These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

582 related items for PubMed ID: 7698170

  • 1. Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.
    Lacour C, Canals F, Galindo G, Cazaubon C, Segondy D, Nisato D.
    Eur J Pharmacol; 1994 Nov 03; 264(3):307-16. PubMed ID: 7698170
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological profile of ME3221, a novel angiotensin II receptor antagonist.
    Nagura J, Yasuda S, Fujishima K, Yamamoto M, Hui C, Kawano K, Katano K, Ogino H, Hachisu M, Konno F.
    Eur J Pharmacol; 1995 Feb 14; 274(1-3):201-11. PubMed ID: 7768273
    [Abstract] [Full Text] [Related]

  • 3. Pharmacology of XR510, a potent orally active nonpeptide angiotensin II AT1 receptor antagonist with high affinity for the AT2 receptor subtype.
    Wong PC, Quan ML, Saye JM, Bernard R, Crain EJ, McCall DE, Watson CA, Zaspel AM, Smith RD, Wexler RR.
    J Cardiovasc Pharmacol; 1995 Sep 14; 26(3):354-62. PubMed ID: 8583775
    [Abstract] [Full Text] [Related]

  • 4. Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats.
    Culman J, von Heyer C, Piepenburg B, Rascher W, Unger T.
    Eur J Pharmacol; 1999 Feb 19; 367(2-3):255-65. PubMed ID: 10079000
    [Abstract] [Full Text] [Related]

  • 5. Effects of U-97018 on pressor responses to intracerebroventricularly administered angiotensin II in conscious normotensive rats.
    Morita O, Kushida H, Kunihara M.
    J Cardiovasc Pharmacol; 1995 Jun 19; 25(6):880-7. PubMed ID: 7564332
    [Abstract] [Full Text] [Related]

  • 6. In vivo pharmacology of SC-51316, a nonpeptidic angiotensin II receptor antagonist.
    Olins GM, Smits GJ, Koepke JP, Huang HC, Reitz DB, Manning RE, Blaine EH.
    Am J Hypertens; 1993 Jul 19; 6(7 Pt 1):619-25. PubMed ID: 8398003
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effects of valsartan in hypertensive models.
    Yamamoto S, Hayashi N, Kometani M, Nakao K, Inukai T.
    Arzneimittelforschung; 1997 May 19; 47(5):604-12. PubMed ID: 9205773
    [Abstract] [Full Text] [Related]

  • 8. EXP597, a nonpeptide angiotensin II receptor antagonist with high affinities for the angiotensin AT1 and AT2 receptor subtypes.
    Wong PC, Duncia JV, Santella JB, Smith RD, Wexler RR, Timmermans PB, Chiu AT.
    Eur J Pharmacol; 1994 Aug 01; 260(2-3):261-4. PubMed ID: 7988654
    [Abstract] [Full Text] [Related]

  • 9. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients.
    Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G.
    Hypertension; 1995 Jan 01; 25(1):37-46. PubMed ID: 7843751
    [Abstract] [Full Text] [Related]

  • 10. Effect of AT1 angiotensin-receptor blockade on structure and function of small arteries in SHR.
    Li JS, Sharifi AM, Schiffrin EL.
    J Cardiovasc Pharmacol; 1997 Jul 01; 30(1):75-83. PubMed ID: 9268224
    [Abstract] [Full Text] [Related]

  • 11. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats.
    Inada Y, Wada T, Shibouta Y, Ojima M, Sanada T, Ohtsuki K, Itoh K, Kubo K, Kohara Y, Naka T.
    J Pharmacol Exp Ther; 1994 Mar 01; 268(3):1540-7. PubMed ID: 8138966
    [Abstract] [Full Text] [Related]

  • 12. Lack of a centrally-mediated antihypertensive effect following acute or chronic central treatment with AT1-receptor antagonists in spontaneously hypertensive rats.
    Bunting MW, Widdop RE.
    Br J Pharmacol; 1995 Dec 01; 116(8):3181-90. PubMed ID: 8719794
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats.
    Wada T, Inada Y, Ojima M, Sanada T, Shibouta Y, Nishikawa K.
    Hypertens Res; 1996 Jun 01; 19(2):75-81. PubMed ID: 10968199
    [Abstract] [Full Text] [Related]

  • 14. Effects of the new angiotensin II type 1 receptor antagonist KRH-594 on several types of experimental hypertension.
    Inada Y, Murakami M, Kaido K, Nakao K.
    Arzneimittelforschung; 1999 Jan 01; 49(1):13-21. PubMed ID: 10028373
    [Abstract] [Full Text] [Related]

  • 15. Effects of the angiotensin II receptor antagonist losartan on 24-hour blood pressure profiles of primary and secondary hypertensive rats.
    Schnecko A, Witte K, Lemmer B.
    J Cardiovasc Pharmacol; 1995 Aug 01; 26(2):214-21. PubMed ID: 7475045
    [Abstract] [Full Text] [Related]

  • 16. Effects of irbesartan (SR47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: potential mechanisms of action.
    Christophe B, Libon R, Cazaubon C, Nisato D, Manning A, Chatelain P.
    Eur J Pharmacol; 1995 Aug 04; 281(2):161-71. PubMed ID: 7589203
    [Abstract] [Full Text] [Related]

  • 17. Protective effects of ME3221 on hypertensive complications and lifespan in salt-loaded stroke-prone spontaneously hypertensive rats.
    Nagura J, Yamamoto M, Hui C, Yasuda S, Hachisu M, Konno F.
    Clin Exp Pharmacol Physiol; 1996 Mar 04; 23(3):229-35. PubMed ID: 8934613
    [Abstract] [Full Text] [Related]

  • 18. Sympatho-inhibitory actions of irbesartan in pithed spontaneously hypertensive and Wistar-Kyoto rats.
    Balt JC, Mathy MJ, Pfaffendorf M, van Zwieten PA.
    Fundam Clin Pharmacol; 2003 Feb 04; 17(1):83-91. PubMed ID: 12588634
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular effects of GR117289, a novel angiotensin AT1 receptor antagonist.
    Hilditch A, Hunt AA, Gardner CJ, Twissell DJ, Polley J, Travers A, Drew GM, Middlemiss D, Ross BC, Robertson MJ.
    Br J Pharmacol; 1994 Jan 04; 111(1):137-44. PubMed ID: 8012689
    [Abstract] [Full Text] [Related]

  • 20. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients.
    Pechère-Bertschi A, Nussberger J, Decosterd L, Armagnac C, Sissmann J, Bouroudian M, Brunner HR, Burnier M.
    J Hypertens; 1998 Mar 04; 16(3):385-93. PubMed ID: 9557932
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.